STI, Hepatitis B/C, and HIV Screening Recommendations for Pregnant Women Illinois Department of Public Health



Intrauterine or perinatally transmitted STIs, Hepatitis B/C, and HIV can have debilitating effects on pregnant women, their partners, and their fetuses. All pregnant women and their sex partners should be questioned and if needed, counseled about the possibility of these infections and access to testing and treatment should be provided.

The **Illinois Department of Public Health** has developed this screening guide for all medical providers responsible for the care of pregnant women. This guide follows the Center for Disease Control and Prevention (CDC) national recommendations for screening and treating pregnant women published in the current CDC, STD Treatment Guidelines.

SYPHILIS SCREENING					
TESTING	Healthcare providers are required by Illinois law (410 ILCS 320/1) to screen all pregnant women for syphilis infection during the first prenatal visit and during the third trimester. - In the event any blood tests shall show a positive or inconclusive result an additional test or tests shall be performed. - Infants should not be discharged from the hospital unless the syphilis serologic status of the mother has been determined at least one time during pregnancy and preferably again at delivery.				
RISK FACTORS	 More than one sex partner in the previous six months Evaluation or treatment for an STI 	Behaviors that constitute an increased risk for an STI			
RE-TEST	Any woman who delivers a stillborn infant after 20 weeks gestation should be tested for syphilis regardless of risk.				
HIV SCREENING					
TESTING	Healthcare providers are required by Illinois law (Public Law 95-702) to screen newborns for HIV if mother's HIV status is unknown. All pregnant women should be screened for HIV during the first prenatal visit. - Screening should be conducted after the woman is notified that she will be screened for HIV as part of the routine panel of prenatal tests, unless she declines (e.g., opt-out screening). For women who decline HIV testing, providers should address their objections and, when appropriate, continue to strongly encourage testing. - Women who decline testing because they have had a previous negative HIV test should be informed of the importance of retesting during each pregnancy.				
RISK FACTORS	•Recent or current injection-drug use •STIs during pregnancy	•Multiple sex partners during pregnancy •Live in areas with high HIV prevalence or have HIV-infected partners			
RE-TEST	Re-testing in the <u>third trimester</u> (preferably before 36 weeks gestation) is recommended for women at high risk for acquiring HIV infection. Rapid HIV screening should be performed on any woman in labor who has an undocumented HIV status unless she declines. If rapid HIV				

test results are reactive, antiretroviral prophylaxis is recommended prior to confirmatory test results.

HEPATITIS B SCREENING All pregnant women should be screened for Hepatitis B surface antigen (HBsAg) during the first prenatal visit of <u>each</u> pregnancy, even if they have been previously vaccinated or tested. Pregnant women who were not screened prenatally should be tested upon admission for delivery. Physical Note than one sex partner in the previous six months Evaluation or treatment for an STI Recent or current injection-drug use Pregnant women who are at high risk for Hepatitis B infection should be <u>re-tested upon admission for delivery</u>.

HEPATITIS C SCREENING

TESTING	All pregnant women at high risk should be screened for Hepatitis C during the first prenatal visit.		
RISK FACTORS	History of injection-drug use	History of blood transfusion or organ transplantation before 1992	

CHLAMYDIA/GONORRHEA SCREENING

TESTING	All pregnant women should be routinely screened for chlamydia/gonorrhea during the first prenatal visit.		
RISK FACTORS	 Women aged 25 years and younger Previous chlamydia/gonorrhea or other STI infection New or multiple sex partners 	Inconsistent condom useCommercial sex workDrug use	
RE-TEST	Pregnant women found to have chlamydial/gonococcal infection during the first trimester should be re-tested within approximately 3-6 months, preferably in the <u>third trimester</u> . Uninfected pregnant women who remain at high risk for chlamydial/gonococcal infection should be re-tested during the <u>third trimester</u> .		

Physicians needing additional information may contact the Illinois Department of Public Health:

Sexually Transmitted Disease Section:	217-782-2747	8:30 a.m. – 5:00 p.m.
HIV Section:	217-524-5983	8:30 a.m. – 5:00 p.m.
Communicable Disease Section:	217-782-2016	8:30 a.m. – 5:00 p.m.
Illinois Perinatal Hotline:	1-800-439-4079	24/7



Additional information on the treatment and follow-up of syphilis, HIV, Hepatitis B, Hepatitis C, chlamydia, and gonorrhea is also available by consulting the CDC's "Sexually Transmitted Diseases Treatment Guidelines, 2015" at www.cdc.gov/std/treatment/